Harrow’s main strengths are its rapid revenue growth, improving core operating metrics, and distinctive position in the ophthalmic market. The combination of a leading compounding platform with a growing stable of high-margin branded products creates multiple revenue streams and close relationships with eyecare providers. A robust innovation agenda and sizable pipeline—particularly in retina and procedure-related therapies—offer multiple avenues for future growth. The expanding asset base and increased equity capital show that the company has been able to attract resources to support its strategy.

Key risks center on financial sustainability and execution. The company continues to post net losses and burn cash, with a growing debt load and weakening liquidity that could limit flexibility if markets tighten or products underperform. The balance sheet is increasingly weighted toward intangibles and receivables, which are less resilient if conditions deteriorate. On the operating side, Harrow faces intense competition from larger drug makers, regulatory and reimbursement uncertainties, and the challenge of successfully integrating acquisitions and launching multiple new products while maintaining high quality and compliance standards.

Looking ahead, Harrow appears positioned for continued top-line expansion as its ophthalmic portfolio matures and new launches roll out, especially in retina and procedure-related segments. At the same time, the company is in a transitional phase where it must convert strong sales growth and a promising pipeline into durable profitability and positive free cash flow. The trajectory of margins, cash generation, and leverage over the next few years will be critical indicators of how well the growth story translates into long-term financial resilience. The outlook is one of meaningful opportunity, balanced by notable financial and execution uncertainties.